

Supplementary material has been published as submitted. It has not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica

Table S1. Medical history, including comorbidities^a, by age group

	<65 years n=1088	≥65 years n=102	P value
Blood and lymphatic system disorders	23 (2.1)	1 (1.0)	.71
Cardiac disorders	50 (4.6)	13 (12.8)	.002
Congenital, familial and genetic disorders	21 (1.9)	2 (2.0)	1.00
Ear and labyrinth disorders	32 (2.9)	11 (10.8)	.001
Endocrine disorders	55 (5.1)	15 (14.7)	.001
Eye disorders	63 (5.8)	17 (16.7)	<.001
Gastrointestinal disorders	164 (15.1)	26 (25.5)	.010
General disorders and administration site conditions	35 (3.2)	7 (6.9)	.08
Hepatobiliary disorders	39 (3.6)	6 (5.9)	.27
Immune system disorders	243 (22.3)	21 (20.6)	.80
Infections and infestations	146 (13.4)	17 (16.7)	.37
Injury, poisoning and procedural complications	64 (5.9)	5 (4.9)	.83
Metabolism and nutrition disorders	283 (26.0)	58 (56.9)	<.001
Musculoskeletal and connective tissue disorders ^b	287 (26.4)	44 (43.1)	<.001
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	45 (4.1)	11 (10.8)	.006
Nervous system disorders	136 (12.5)	16 (15.7)	.35
Pregnancy, puerperium and perinatal conditions	4 (0.4)	0 (0)	NA
Psychiatric disorders	194 (17.8)	23 (22.6)	.23
Renal and urinary disorders	50 (4.6)	8 (7.8)	.15
Reproductive system and breast disorders	52 (4.8)	16 (15.7)	<.001
Respiratory, thoracic and mediastinal disorders	124 (11.4)	20 (19.6)	.02
Social circumstances	39 (3.6)	9 (8.8)	.02
Surgical and medical procedures	221 (20.3)	31 (30.4)	.02
Vascular disorders	265 (24.4)	72 (70.6)	<.001

Data shown as No. (%).^a Comorbidities defined as diseases in the medical history that are classically considered to be associated/related/derived from psoriasis; ^b Including psoriatic arthritis.

NA: Not Applicable.

Table SII. Concomitant medications over the 5-year study period

	From baseline to W28		W28 to W52		W52 to W244	
	≥65 years (n=102)	<65 years (n=1088)	<65 years (n=514)	≥65 years (n=42)	<65 years (n=514)	≥65 years (n=42)
ACE inhibitors	23 (22.6)	81 (7.4)	37 (7.2)	9 (21.4)	65 (12.7)	12 (28.6)
Acetic acid derivatives	2 (2.0)	38 (3.5)	3 (7.1)	15 (2.9)	62 (12.1)	6 (14.3)
Amides	3 (2.9)	18 (1.7)	3 (7.1)	9 (1.8)	41 (8.0)	4 (9.5)
Aminoalkyl ethers	3 (2.9)	29 (2.7)	1 (2.4)	17 (3.3)	28 (5.5)	3 (7.1)
Angiotensin II antagonists	23 (22.6)	73 (6.7)	37 (7.2)	9 (21.4)	35 (6.8)	9 (21.4)
Angiotensin II receptor blockers	NA	NA	NA	NA	47 (9.14)	11 (26.2)
Anilides	11 (10.8)	188 (17.3)	74 (14.4)	7 (16.7)	149 (29.0)	13 (31.0)
Benzodiazepine derivatives	5 (4.9)	57 (5.2)	30 (5.8)	3 (7.1)	57 (11.1)	9 (21.4)
Beta blocking agents	17 (16.7)	54 (5.0)	26 (5.1)	6 (14.3)	35 (6.8)	7 (16.7)
Biguanides	13 (12.8)	62 (5.7)	31 (6.0)	4 (9.5)	46 (9.0)	6 (14.3)
First generation cephalosporins	3 (2.9)	21 (1.9)	1 (2.4)	6 (1.2)	31 (6.0)	1 (2.4)
Third generation cephalosporins	1 (1.0)	14 (1.3)	1 (1.0)	14 (1.3)	27 (5.3)	3 (7.1)
Dihydropyridine derivatives	17 (16.7)	46 (4.2)	8 (19.1)	20 (3.9)	37 (7.2)	13 (31.0)
Fluoroquinolones	2 (2.0)	31 (2.9)	1 (2.4)	16 (3.1)	69 (13.4)	5 (11.9)
Glucocorticoids	5 (4.9)	40 (3.7)	29 (5.6)	5 (11.9)	78 (15.2)	8 (19.1)
Heparin	3 (2.9)	6 (0.6)	NA	9 (1.8)	26 (5.1)	2 (4.8)
HMG CoA reductase inhibitors	34 (33.3)	98 (9.0)	52 (10.1)	11 (26.2)	74 (14.4)	18 (42.9)
Influenza vaccines	8 (7.8)	29 (2.7)	6 (14.3)	13 (2.5)	34 (6.6)	9 (21.4)
Macrolides	8 (7.8)	32 (2.9)	2 (4.8)	14 (2.7)	53 (10.3)	6 (14.3)
Mucolytics	4 (3.9)	17 (1.6)	1 (2.4)	7 (1.4)	29 (5.6)	4 (9.5)
Opioids combined with non-opioid analgesics	NA	NA	NA	NA	32 (6.2)	2 (4.8)
Combination of penicillins (including beta-lactamase inhibitors)	NA	12 (1.1)	NA	12 (1.1)	35 (6.8)	3 (7.1)
Penicillins with extended spectrum	6 (5.9)	36 (3.3)	6 (5.9)	36 (3.3)	68 (13.2)	8 (19.1)
Propionic acid derivatives	12 (11.8)	188 (17.3)	95 (18.5)	6 (14.3)	171 (33.3)	12 (28.6)
Proton pump inhibitors	17 (16.7)	83 (7.6)	54 (10.5)	13 (31.0)	107 (20.8)	14 (33.3)

Salicylic acid & derivatives	31 (30.4)	98 (9.0)	51 (10.5)	12 (28.6)	85 (16.5)	14 (33.3)
Selective beta-2-adrenoceptor agonists	5 (4.9)	30 (2.8)	5 (4.9)	30 (2.8)	36 (7.0)	1 (2.4)
Selective serotonin reuptake inhibitors	7 (6.9)	62 (5.7)	35 (6.8)	3 (7.1)	48 (9.3)	6 (14.3)
Thyroid hormones	14 (13.7)	42 (3.9)	29 (5.6)	8 (19.1)	33 (6.4)	8 (19.1)

Data shown as No. (%). Only concomitant medications present in at least 5% of one of the groups are reported.

ACE: Angiotensin-Converting-Enzyme; HMG CoA: Hydroxymethylglutaryl-CoA; NA: Not Applicable; W: week.

Table SIII. Mixed model on the evolution of absolute PASI at weeks 28 and 244 (observed case approach)

	Week 28	Week 244
Effect	P value	
Age group	.53	.10
PASI baseline	<.001	<.001
Treatment	<.001	.02
BMI (kg/m ²)	.30	.001
Week	<.001	.15
Prior biological therapy for psoriasis	.37	.014
Smoking habit	<.001	.007
Diabetes	.54	.57
History of psoriatic arthritis	.14	.86
Age group x week	.46	.003

BMI: Body Mass Index; PASI: Psoriasis Area and Severity Index.

Table Siv. Mixed model on the evolution of absolute PASI at weeks 28 and 244 (multiple imputation approach)

	Week 28	Week 244
Effect	P value	
Intercept	<.001	.94
Age group	.18	.07
PASI baseline	<.001	<.001
Treatment	<.001	.13
BMI (kg/m ²)	.32	.02
Week		
0 versus 28 (W28) / 28 versus 244 (W244)	<.001	.01
4 versus 28 (W28) / 32 versus 244 (W244)	<.001	.001
8 versus 28 (W28) / 36 versus 244 (W244)	<.001	.001
12 versus 28 (W28) / 40 versus 244 (W244)	<.001	.008
16 versus 28 (W28) / 52 versus 244 (W244)	<.001	.71
22 versus 28 (W28) / 60 versus 244 (W244)	.31	.18
64 versus 244 (W244)	NA	.75
76 versus 244 (W244)	NA	.98
88 versus 244 (W244)	NA	.28
100 versus 244 (W244)	NA	.22
112 versus 244 (W244)	NA	.10
124 versus 244 (W244)	NA	.23
136 versus 244 (W244)	NA	.47
148 versus 244 (W244)	NA	.20
172 versus 244 (W244)	NA	.09
196 versus 244 (W244)	NA	.10
220 versus 244 (W244)	NA	.27
Prior biological therapy for psoriasis	.44	.002
Smoking habit		
Current user versus never used tobacco	<.001	.004
Ex user versus never used tobacco	.59	.79
Diabetes	.69	.62

History of psoriatic arthritis	.12	.79
Age group x week		
0 versus 28 (W28) / 28 versus 244 (W244)	.02	.05
4 versus 28 (W28) / 32 versus 244 (W244)	.13	.06
8 versus 28 (W28) / 36 versus 244 (W244)	.45	.04
12 versus 28 (W28) / 40 versus 244 (W244)	.65	.11
16 versus 28 (W28) / 52 versus 244 (W244)	.82	.27
22 versus 28 (W28) / 60 versus 244 (W244)	.83	.49
64 versus 244 (W244)	NA	.60
76 versus 244 (W244)	NA	.21
88 versus 244 (W244)	NA	.37
100 versus 244 (W244)	NA	.63
112 versus 244 (W244)	NA	.70
124 versus 244 (W244)	NA	.46
136 versus 244 (W244)	NA	.62
148 versus 244 (W244)	NA	.73
172 versus 244 (W244)	NA	.92
196 versus 244 (W244)	NA	1.00
220 versus 244 (W244)	NA	.78

BMI: Body Mass Index; NA: Not Applicable; PASI: Psoriasis Area and Severity Index; W: week.